Replimune Group, Inc. Profile Avatar - Palmy Investing

Replimune Group, Inc.

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against canc…

Biotechnology
US, Woburn [HQ]
Major Shareholders · Proxy Ben. Owners

Shareholders

Breakdown
Institutional
Insider
Retail
92.17%
4.18%
3.65%
Intraday
Shares Outstanding
75,340,500
Volume
364,689
Volume on Avg.
797,211
Beneficial Owners Beta
SEC Source
Owner Shares Equivalence - $10.50 per share Last Form/Filing Last Transaction
10% Holder
- No data -
Officers/Directors Below 10%
- No data -
End of REPL's Analysis
CIK: 1737953 CUSIP: 76029N106 ISIN: US76029N1063 LEI: - UEI: -
Secondary Listings
REPL has no secondary listings inside our databases.